BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mylin AK, Abildgaard N, Johansen JS, Heickendorff L, Kreiner S, Waage A, Turesson I, Gimsing P; Nordic Myeloma Study Group. Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma. Leuk Lymphoma 2015;56:2650-9. [PMID: 25573204 DOI: 10.3109/10428194.2015.1004168] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Li L, Fan J, Li D, Liu Y, Shrestha P, Zhong C, Xia X, Huang X. Influence of YKL-40 gene RNA interference on the biological behaviors of endometrial cancer HEC-1A cells. Oncol Lett 2018;16:1777-84. [PMID: 30008865 DOI: 10.3892/ol.2018.8814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Kirwan A, Utratna M, O'Dwyer ME, Joshi L, Kilcoyne M. Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics. Biomed Res Int 2015;2015:490531. [PMID: 26509158 DOI: 10.1155/2015/490531] [Cited by in Crossref: 93] [Cited by in F6Publishing: 81] [Article Influence: 13.3] [Reference Citation Analysis]
3 Tibullo D, Di Rosa M, Giallongo C, La Cava P, Parrinello NL, Romano A, Conticello C, Brundo MV, Saccone S, Malaguarnera L, Di Raimondo F. Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. Front Pharmacol 2015;6:226. [PMID: 26528182 DOI: 10.3389/fphar.2015.00226] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
4 Afinogenova Y, Ruan J, Yang R, Kleytman N, Pastores G, Lischuk A, Mistry PK. Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease. Mol Genet Metab 2019;128:62-7. [PMID: 31358474 DOI: 10.1016/j.ymgme.2019.07.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
5 Zadi Heydarabad M, Baharaghdam S, Azimi A, Mohammadi H, Eivazi Ziaei J, Yazdanpanah B, Zak MS, Farahani ME, Dohrabpour A, Partash N, Talebi M. The role of tumor suppressor of resveratrol and prednisolone by downregulation of YKL-40 expression in CCRF-CEM cell line. J Cell Biochem 2019;120:3773-9. [PMID: 30426549 DOI: 10.1002/jcb.27659] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Bao Y, Zhang W, Shi D, Bai W, He D, Wang D. Correlation Between Serum Tumor Marker Levels and Connective Tissue Disease-Related Interstitial Lung Disease. Int J Gen Med 2021;14:2553-60. [PMID: 34163223 DOI: 10.2147/IJGM.S310917] [Reference Citation Analysis]
7 Sanchez C, Mazzucchelli G, Lambert C, Comblain F, DePauw E, Henrotin Y. Comparison of secretome from osteoblasts derived from sclerotic versus non-sclerotic subchondral bone in OA: A pilot study. PLoS One 2018;13:e0194591. [PMID: 29547667 DOI: 10.1371/journal.pone.0194591] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
8 Ngernyuang N, Yan W, Schwartz LM, Oh D, Liu YB, Chen H, Shao R. A Heparin Binding Motif Rich in Arginine and Lysine is the Functional Domain of YKL-40. Neoplasia 2018;20:182-92. [PMID: 29274508 DOI: 10.1016/j.neo.2017.11.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Westhrin M, Moen SH, Holien T, Mylin AK, Heickendorff L, Olsen OE, Sundan A, Turesson I, Gimsing P, Waage A, Standal T. Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease. Haematologica 2015;100:e511-4. [PMID: 26294726 DOI: 10.3324/haematol.2015.124511] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
10 Guo W, Wang J, Wei H. Serum YKL-40 Level Positively Correlates With Uterine Leiomyomas. Reprod Sci 2016;23:1559-64. [DOI: 10.1177/1933719116648219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Yeo IJ, Lee CK, Han SB, Yun J, Hong JT. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol Ther 2019;203:107394. [PMID: 31356910 DOI: 10.1016/j.pharmthera.2019.107394] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
12 Mylin AK, Goetze JP, Heickendorff L, Ahlberg L, Dahl IM, Abildgaard N, Gimsing P; for the Nordic Myeloma Study Group. N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma. Biomarkers in Medicine 2015;9:679-89. [DOI: 10.2217/bmm.15.35] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Steinke J, Samietz S, Friedrich N, Weiss S, Michalik S, Biffar R, Nauck M, Völker U, Wallaschofski H, Pietzner M, Hannemann A. Associations of plasma YKL-40 concentrations with heel ultrasound parameters and bone turnover markers in the general adult population. Bone 2020;141:115675. [PMID: 33031973 DOI: 10.1016/j.bone.2020.115675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Silsirivanit A. Glycosylation markers in cancer. Adv Clin Chem 2019;89:189-213. [PMID: 30797469 DOI: 10.1016/bs.acc.2018.12.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 9.3] [Reference Citation Analysis]
15 Pérez-García S, Calamia V, Hermida-Gómez T, Gutiérrez-Cañas I, Carrión M, Villanueva-Romero R, Castro D, Martínez C, Juarranz Y, Blanco FJ, Gomariz RP. Proteomic Analysis of Synovial Fibroblasts and Articular Chondrocytes Co-Cultures Reveals Valuable VIP-Modulated Inflammatory and Degradative Proteins in Osteoarthritis. Int J Mol Sci 2021;22:6441. [PMID: 34208590 DOI: 10.3390/ijms22126441] [Reference Citation Analysis]